Dr. Huma Qamar’s Innovating Impact on Healthcare

Dr. Huma Qamar is a distinguished healthcare figure known for her relentless commitment to excellence. As the Chief Scientific Officer and Head of Research and Development at Medicus Pharma, she has made remarkable contributions to advancing medical innovation.

Dr. Huma began her journey almost a decade ago with only determination and a mere $100 in her pocket. Born in Rawalpindi, Pakistan, she traveled to the United States, driven by a profound desire to pursue her dreams and ambitions.

“Like any other immigrant, I knew that the USA was the land of opportunities, and here I could achieve my dreams through hard work and perseverance,” Dr. Huma shares.

She saw America as a place where she could carve out her destiny. After graduating from medical school, she seized an excellent clinical research opportunity at Yale University, beginning her illustrious professional journey.

Her path was not without its challenges. As a single immigrant navigating the healthcare landscape, Dr. Huma had to work five times harder than others. However, she still made significant strides in the scientific community, blending her passion for public health, clinical research, and medicine to benefit the communities of the Greater Philadelphia Area.

Throughout her career, Dr. Huma has left a memorable mark on prestigious institutions such as Yale, Harvard, and the University of Pennsylvania, as well as outstanding hospitals like Thomas Jefferson University Hospital and The Children’s Hospital of Philadelphia.

Today, Dr. Huma serves as the Chief Scientific Officer and Head of Research and Development at Medicus Pharma. She is deeply engaged in derm-oncology, leading efforts to revolutionize the treatment of basal cell carcinoma.

“I am currently overseeing the Phase 2 Basal Cell Carcinoma trial utilizing a novel Microneedle array approach to treat the skin cancer with minimum invasion and pain.” Dr. Huma mentions.

Dr. Huma’s latest endeavors include cutting-edge gene therapy and artificial intelligence projects. At Ocugen, she has contributed to a new modifier gene therapy clinical development program targeting inherited retinal diseases, Geographic Atrophy, and Stargardt diseases.

Dr. Huma is looking to explore the field of Artificial Intelligence to broaden her horizons for upcoming projects. She has a vision of introducing AI models in the United States and Gulf countries, recognizing ample opportunities for collaborative efforts to foster scientific innovation worldwide.

She also aspires to make a lasting impact on the healthcare landscape by assuming a leadership position as a Chief Executive Officer, where she can create a more significant, meaningful impact.

Dr. Huma advises aspiring medical graduates to adopt a forward-thinking mindset, emphasizing the significance of gaining clinical experience beyond textbook knowledge.

“My advice, especially to foreign medical graduates (MDs), is to think outside the box and see prospectively how the scientific/clinical research industry will look in the next 5-7 years.” Dr. Huma emphasizes. 

As a visionary leader and trailblazer in clinical research and medical innovation, Dr. Huma continues to inspire through her inspiring contributions, shaping the future of healthcare for generations to come.

To learn more about Dr. Huma Qamar’s medical journey, click here.